세계의 신장병용 케토아날로그(Ketoanalogue) 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)
Global Ketoanalogue For Kidney Disease Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
상품코드:1820511
리서치사:Value Market Research
발행일:2025년 09월
페이지 정보:영문 106 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 신장병용 케토아날로그 시장은 대폭적인 성장이 전망되고 있어 시장 규모는 2024년 2억 7,749만 달러에서 2033년에는 4억 9,869만 달러로 급증하고, 예측 기간중 연평균 복합 성장률(CAGR)은 6.73%를 나타낼 것으로 예측됩니다.
세계적으로 만성콩팥병(CKD) 유병률이 증가하고 질병 진행을 늦추는 치료 전략이 발전함에 따라 신장 질환용 케토아날로그 시장이 확대되고 있습니다. 저단백 식단의 영양 보충제로 사용되는 케토아날로그는 질소 노폐물 축적을 억제하고 신장 기능을 유지하는 데 도움이 됩니다. 제형과 전달 방법의 발전으로 생체이용률, 환자 순응도, 영양 균형이 개선되고 있습니다. 케토아날로그 요법과 맞춤 영양요법 및 다학제적 치료의 통합은 임상 결과를 개선하고 있습니다.
CKD 관리와 조기 개입에 대한 인식이 높아지면서 선진국과 신흥국 시장 모두에서 수요가 증가하고 있습니다. 규제 당국의 승인과 상환 정책이 시장 진입을 촉진하고 있습니다. 병용요법이나 새로운 유사 약물에 대한 연구로 치료의 선택지가 넓어지고 있습니다. 또한, 원격 의료 및 디지털 헬스 플랫폼이 환자 모니터링과 순응도를 지원하고 있습니다.
제약회사, 신장 전문의, 의료 서비스 제공업체 간의 협업은 기술 혁신과 교육을 가속화하고 있습니다. CKD의 부담이 증가함에 따라 케토아날로그 시장은 환자의 삶의 질을 개선하고 투석 시작을 늦추기 위한 효과적인 영양 지원을 제공함으로써 성장할 수 있는 여건을 마련하고 있습니다.
목차
제1장 서문
제2장 주요 요약
시장 하이라이트
세계 시장 현황
제3장 신장병용 케토아날로그-업계 분석
서론 : 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
업계 동향
Porter의 Five Forces 분석
시장 매력 분석
제4장 밸류체인 분석
밸류체인 분석
원재료 분석
원재료 리스트
원재료 제조업체 리스트
주요 원재료 가격 동향
잠재적 바이어 리스트
마케팅 채널
직접 마케팅
간접 마케팅
마케팅 채널 발전 동향
제5장 세계의 신장병용 케토아날로그 시장 분석 : 용도별
개요 : 용도별
과거 및 예측 데이터 분석 : 용도별
만성 신장병(CKD)
급성 신부전
기타
제6장 세계의 신장병용 케토아날로그 시장 분석 : 최종사용자별
최종사용자별 개요
최종사용자별 : 과거 및 예측 데이터 분석
병원 약국
소매 약국
온라인 약국
제7장 세계의 신장병용 케토아날로그 시장 분석 : 지역별
지역별 전망
서론
북미 : 판매 분석
개요, 분석과 예측
북미 : 부문별
북미, 국가별
미국
캐나다
멕시코
유럽 : 판매 분석
개요, 분석과 예측
유럽 : 부문별
유럽 : 국가별
영국
프랑스
독일
이탈리아
러시아
기타 유럽
아시아태평양의 판매 분석
개요, 분석과 예측
아시아태평양 : 부문별
아시아태평양, 국가별
중국
인도
일본
한국
호주
동남아시아
기타 아시아태평양
라틴아메리카 : 판매 분석
개요, 분석과 예측
라틴아메리카 : 부문별
라틴아메리카 : 국가별
브라질
아르헨티나
페루
칠레
기타 라틴아메리카
중동 및 아프리카의 판매 분석
개요, 분석과 예측
중동 및 아프리카 부문별
중동 및 아프리카 국가별 리스트
사우디아라비아
아랍에미리트(UAE)
이스라엘
남아프리카공화국
기타 중동 및 아프리카
제8장 신장병용 케토아날로그 기업 경쟁 구도
신장병용 케토아날로그 시장 경쟁
제휴, 협력 및 합의
인수합병(M&A)
신제품 출시
기타 개발
제9장 기업 개요
주요 기업의 시장 점유율 분석
시장 집중도
Fresenius Kabi AG
RPG Life Sciences Ltd.
Alniche Life Sciences Pvt. Ltd.
La Renon Healthcare Pvt. Ltd.
Steadfast Medishield Pvt. Ltd.
Panacea Biotec Ltd.
Element Inc.
Ajanta Pharma Limited
Centaur Pharmaceuticals
Genix Lifescience Pvt. Ltd
LSH
영문 목차
영문목차
Global Ketoanalogue For Kidney Disease Market is poised for a significant growth, with market size projected to surge from USD 277.49 Million in 2024 to USD 498.69 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 6.73% during the forecast period.
The ketoanalogue for kidney disease market is expanding as chronic kidney disease (CKD) prevalence rises globally and therapeutic strategies evolve to delay disease progression. Ketoanalogues, used as dietary supplements in low-protein diets, help reduce nitrogenous waste accumulation and preserve renal function. Advances in formulation and delivery methods are improving bioavailability, patient compliance, and nutritional balance. The integration of ketoanalogue therapy with personalized nutrition and multidisciplinary care is enhancing clinical outcomes.
Increasing awareness of CKD management and early intervention is driving demand in both developed and emerging markets. Regulatory approvals and reimbursement policies are facilitating market access. Research into combination therapies and novel analogues is expanding therapeutic options. Additionally, telemedicine and digital health platforms are supporting patient monitoring and adherence.
Collaborations among pharmaceutical companies, nephrologists, and healthcare providers are accelerating innovation and education. As CKD burden intensifies, the ketoanalogue market is poised for growth, offering effective nutritional support to improve patient quality of life and delay dialysis initiation.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
LIST OF SEGMENTS COVERED
This section of the Ketoanalogue For Kidney Disease market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Application
Chronic Kidney Disease (CKD)
Acute Renal Failure
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
List of Companies Profiled in the report
Fresenius Kabi AG, RPG Life Sciences Ltd., Alniche Life Sciences Pvt. Ltd., La Renon Healthcare Pvt. Ltd., Steadfast Medishield Pvt. Ltd., Panacea Biotec Ltd., Element Inc., Ajanta Pharma Limited, Centaur Pharmaceuticals, Genix Lifescience Pvt. Ltd.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3. KETOANALOGUE FOR KIDNEY DISEASE - INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Application
3.7.2 Market Attractiveness Analysis By End-User
3.7.3 Market Attractiveness Analysis By Regions
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL KETOANALOGUE FOR KIDNEY DISEASE MARKET ANALYSIS BY APPLICATION
5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Chronic Kidney Disease (CKD) Historic and Forecast Sales By Regions
5.4. Acute Renal Failure Historic and Forecast Sales By Regions
5.5. Others Historic and Forecast Sales By Regions
6. GLOBAL KETOANALOGUE FOR KIDNEY DISEASE MARKET ANALYSIS BY END-USER
6.1. Overview By End-User
6.2. Historical and Forecast Data Analysis By End-User
6.3. Hospital Pharmacies Historic and Forecast Sales By Regions
6.4. Retail Pharmacies Historic and Forecast Sales By Regions
6.5. Online Pharmacies Historic and Forecast Sales By Regions
7. GLOBAL KETOANALOGUE FOR KIDNEY DISEASE MARKET ANALYSIS BY GEOGRAPHY
7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
7.3.1 Overview, Historic and Forecast Data Sales Analysis
7.3.2 North America By Segment Sales Analysis
7.3.3 North America By Country Sales Analysis
7.3.4 United States Sales Analysis
7.3.5 Canada Sales Analysis
7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
7.4.1 Overview, Historic and Forecast Data Sales Analysis
7.4.2 Europe By Segment Sales Analysis
7.4.3 Europe By Country Sales Analysis
7.4.4 United Kingdom Sales Analysis
7.4.5 France Sales Analysis
7.4.6 Germany Sales Analysis
7.4.7 Italy Sales Analysis
7.4.8 Russia Sales Analysis
7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
7.5.1 Overview, Historic and Forecast Data Sales Analysis
7.5.2 Asia Pacific By Segment Sales Analysis
7.5.3 Asia Pacific By Country Sales Analysis
7.5.4 China Sales Analysis
7.5.5 India Sales Analysis
7.5.6 Japan Sales Analysis
7.5.7 South Korea Sales Analysis
7.5.8 Australia Sales Analysis
7.5.9 South East Asia Sales Analysis
7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
7.6.1 Overview, Historic and Forecast Data Sales Analysis
7.6.2 Latin America By Segment Sales Analysis
7.6.3 Latin America By Country Sales Analysis
7.6.4 Brazil Sales Analysis
7.6.5 Argentina Sales Analysis
7.6.6 Peru Sales Analysis
7.6.7 Chile Sales Analysis
7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
7.7.1 Overview, Historic and Forecast Data Sales Analysis
7.7.2 Middle East & Africa By Segment Sales Analysis
7.7.3 Middle East & Africa By Country Sales Analysis
7.7.4 Saudi Arabia Sales Analysis
7.7.5 UAE Sales Analysis
7.7.6 Israel Sales Analysis
7.7.7 South Africa Sales Analysis
7.7.8 Rest Of Middle East And Africa Sales Analysis
8. COMPETITIVE LANDSCAPE OF THE KETOANALOGUE FOR KIDNEY DISEASE COMPANIES
8.1. Ketoanalogue For Kidney Disease Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments
9. COMPANY PROFILES OF KETOANALOGUE FOR KIDNEY DISEASE INDUSTRY
9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Fresenius Kabi AG
9.3.1 Company Overview
9.3.2 Company Revenue
9.3.3 Products
9.3.4 Recent Developments
9.4. RPG Life Sciences Ltd.
9.4.1 Company Overview
9.4.2 Company Revenue
9.4.3 Products
9.4.4 Recent Developments
9.5. Alniche Life Sciences Pvt. Ltd.
9.5.1 Company Overview
9.5.2 Company Revenue
9.5.3 Products
9.5.4 Recent Developments
9.6. La Renon Healthcare Pvt. Ltd.
9.6.1 Company Overview
9.6.2 Company Revenue
9.6.3 Products
9.6.4 Recent Developments
9.7. Steadfast Medishield Pvt. Ltd.
9.7.1 Company Overview
9.7.2 Company Revenue
9.7.3 Products
9.7.4 Recent Developments
9.8. Panacea Biotec Ltd.
9.8.1 Company Overview
9.8.2 Company Revenue
9.8.3 Products
9.8.4 Recent Developments
9.9. Element Inc.
9.9.1 Company Overview
9.9.2 Company Revenue
9.9.3 Products
9.9.4 Recent Developments
9.10. Ajanta Pharma Limited
9.10.1 Company Overview
9.10.2 Company Revenue
9.10.3 Products
9.10.4 Recent Developments
9.11. Centaur Pharmaceuticals
9.11.1 Company Overview
9.11.2 Company Revenue
9.11.3 Products
9.11.4 Recent Developments
9.12. Genix Lifescience Pvt. Ltd
9.12.1 Company Overview
9.12.2 Company Revenue
9.12.3 Products
9.12.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies
